MedTrace Logo

Test Albuvirtide in Experienced Patients

NCT02369965 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2021-10-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral therapy (ART).

Conditions

  • HIV Infections
  • AIDS

Interventions

DRUG

albuvirtide

albuvirtide 320mg administered intravenously once a week

DRUG

lopinavir-ritonavir

lopinavir-ritonavir 400/100mg administered orally twice daily

DRUG

tenofovir

tenofovir 300mg administered orally once daily

DRUG

lamivudine

lamivudine 300mg administered orally once daily

Sponsors & Collaborators

  • Frontier Biotechnologies Inc.

    lead INDUSTRY

Principal Investigators

  • Dong Xie · Frontier Biotechnologies Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-19
Primary Completion
2018-04-02
Completion
2018-04-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02369965 on ClinicalTrials.gov